Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis : interim 2-year analysis from SERENA
Abstract
The safety set comprised 189 patients (PsA, n = 81; r-axSpA, n = 108), and the target population set comprised 183 patients (PsA, n = 78; r-axSpA, n = 105). In the safety set, 107 patients (45 of 81 with PsA and 62 of 108 with r-axSpA) had previously received a biologic agent. Retention rates were similar between patients with PsA and r-axSpA after 1 year (PsA 91.0%, 95% CI: 84.0, 98.0; r-axSpA 89.2%, 95% CI: 82.7, 95.7) and 2 years (PsA 77.6%, 95% CI: 67.6, 87.7; r-axSpA 76.2%, 95% CI: 67.4, 85.0) of observation. Overall, 17.5% of patients (33 of 189) experienced at least one treatment-related adverse event, and 12.7% of patients (24 of 189) discontinued secukinumab because of adverse events.
Author
Citations
Altmetric:
Date
2023-08-21
Type
Article
Subject
Rheumatology
Collections
Citation
Rheumatol Adv Pract
. 2023 Aug 21;7(3):rkad055
Journal / Source Title
Rheumatology Advances in Practice
DOI
10.1093/rap/rkad055
PMID
37663578
Publisher
Oxford University Press
Publisher’s URL
https://doi.org/10.1093/rap/rkad055